Cancer is a disease that is feared by many, reason being it has been associated with the death of many people. Committed scientists have worked hard to invent treatment and anti-cancer drugs. One such scientist is Mikhail Blagosklonny a distinguished oncology professor. His passion for seeing a disease free world motivates him for researching on molecular and cellular biology and biogerontology. He clinically investigates cancer therapies and antiaging drugs and he has been known for his advocacy for rapamycin.
Blagosklonny has a hypothesis TOR signaling in cancer and aging and hence his proposal for rapamycin as a cancer treatment for life extension.
He attended First Pavlov State Medical University St Petersburg where he attained his Ph.D. in Experimental medicine and cardiology and MD in Internal Medicine.
Blagosklonny is currently an oncology professor at the Roswell Park University a position he holds since 2009.
The dedicated researcher is an editor-in-chief of Cell Cycle, Oncotarget, and Aging and is an associate editor of PLOS ONE and Cancer Biology and Therapy. Mikhail Blagosklonny is a member of the editorial board of The American Journal of Pathology, Cell Death and Differentiation, Autophagy and International Journal of Cancer. He has more than 250 published book chapters, research articles, and reviews. He continues his research in cell cycle, mitosis, anticancer therapeutics, apoptosis, and ontogenesis and tumor suppressors to come up with treatments that will curb death associated with cancer. Follow Mikhail on Google Scholar